Potential use of radiolabeled antisense oligonucleotides in oncology.
Antisense oligodeoxynucleotides (ODNs) have great promise for therapy. Oligomers labeled with gamma-emitting radioelements have great promise for diagnosis. These radiolabeled oligomers can be used to identify the presence of a particular messenger RNA through simple external detection of radioactivity by means of scintigraphy. This review evaluates the progress in the development of antisense oligodeoxynucleotides for non-invasive imaging of chemoresistance. As nominated by H.N. Wagner at the final session of Nuclear Medicine congress in Denver, the deoxyribonucleic acid is "the molecule of the millennium".
Gauchez
A S
AS
Laboratoire d'Etude des Radiopharmaceutiques, ESA CNRS 5077, Université J. Fourier, Grenoble, France.
Du Moulinet D'Hardemare
A
A
Lunardi
J
J
Vuillez
J P
JP
Fagret
D
D
D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000627:therapeutic use*; D011868:Radioisotopes / Q000737:chemistry*
D016376:Oligonucleotides, Antisense; D011868:Radioisotopes